Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC

April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention of influenza and COVID-19 in adults 50 years of age and older. Here are the details: • The approval follows a positive recommendation from the European Medicines Agency,

In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for resubmission remains uncertain.

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines.

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices ...

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April